{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:53:48Z","timestamp":1784202828086,"version":"3.55.0"},"reference-count":44,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Infliximab (IFX) is a monoclonal tumor necrosis factor-\u03b1\u2013inhibiting antibody used in children with refractory arthritis and uveitis. Immunogenicity is associated with a lack of clinical response and infusion reactions in adults; data on immunogenicity in children treated with IFX for rheumatic diseases are scarce. We aimed to describe the prevalence of anti-IFX antibodies and determine co-factors associated with anti-IFX antibodies in children with inflammatory rheumatic and ocular diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Consecutive children treated between August 2009 and August 2012 with IFX at our department were included. Blood samples were collected every 6 months before IFX infusion and tested for anti-IFX antibodies by radioimmunoassay. Patients\u2019 charts were retrospectively reviewed for clinical features and analyzed for associations with anti-IFX antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Anti-IFX antibodies occurred in 14\/62 children (23%) and 32\/253 blood samples (12.6%) after a mean treatment time of 1084 days (range 73\u20133498). Infusion reactions occurred in 10\/62 (16%) children during the treatment period. With continuation of IFX, anti-IFX antibodies disappeared in 7\/14 children. In the bivariate analysis, the occurrence of anti-IFX antibodies was associated with younger age at IFX treatment start (mean age 7.01 vs 9.88 yrs, p = 0.003) and infusion reactions (OR 15.0), while uveitis as treatment indication was protective against development of anti-IFX antibodies (OR 0.17), likely because of higher IFX doses. In the multivariate logistic regression, all 3 covariates remained highly significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Anti-IFX antibodies occurred commonly at any time during IFX treatment. Anti-IFX antibodies were associated with younger age at IFX start, infusion reactions, and arthritis as treatment indication.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.160072","type":"journal-article","created":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T01:10:26Z","timestamp":1484529026000},"page":"334-341","source":"Crossref","is-referenced-by-count":12,"title":["Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and\/or Uveitis: A Retrospective Longitudinal Cohort Study"],"prefix":"10.3899","volume":"44","author":[{"given":"Florence A.","family":"Aeschlimann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Angst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Cannizzaro Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Schroeder-Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Lauener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9e","family":"van der Kleij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotraud K.","family":"Saurenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2017,1,15]]},"reference":[{"key":"2018112909364726000_44.3.334.1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20460"},{"key":"2018112909364726000_44.3.334.2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.124081"},{"key":"2018112909364726000_44.3.334.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.01.005"},{"key":"2018112909364726000_44.3.334.4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22087"},{"key":"2018112909364726000_44.3.334.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.20793"},{"key":"2018112909364726000_44.3.334.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.4"},{"key":"2018112909364726000_44.3.334.7","first-page":"18","article-title":"Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis","volume":"26","author":"Figueiredo","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909364726000_44.3.334.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110956"},{"key":"2018112909364726000_44.3.334.9","first-page":"1912","article-title":"Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number","volume":"31","author":"Wasserman","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909364726000_44.3.334.10","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e318208451d"},{"key":"2018112909364726000_44.3.334.11","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20246"},{"key":"2018112909364726000_44.3.334.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.22838"},{"key":"2018112909364726000_44.3.334.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.100354"},{"key":"2018112909364726000_44.3.334.14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-13-184"},{"key":"2018112909364726000_44.3.334.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.21671"},{"key":"2018112909364726000_44.3.334.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092833"},{"key":"2018112909364726000_44.3.334.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131231"},{"key":"2018112909364726000_44.3.334.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.22214"},{"key":"2018112909364726000_44.3.334.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057406"},{"key":"2018112909364726000_44.3.334.20","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328329ed8b"},{"key":"2018112909364726000_44.3.334.21","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"2018112909364726000_44.3.334.22","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.099978"},{"key":"2018112909364726000_44.3.334.23","first-page":"1991","article-title":"Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997","volume":"25","author":"Petty","year":"1998","journal-title":"J Rheumatol"},{"key":"2018112909364726000_44.3.334.24","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909364726000_44.3.334.25","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12030"},{"key":"2018112909364726000_44.3.334.26","unstructured":"Kirkwood BR Sterne JAC . Essential medical statistics. Hoboken: Wiley; 2013."},{"key":"2018112909364726000_44.3.334.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6632.1313"},{"key":"2018112909364726000_44.3.334.28","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R"},{"key":"2018112909364726000_44.3.334.29","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283521c4e"},{"key":"2018112909364726000_44.3.334.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.06.011"},{"key":"2018112909364726000_44.3.334.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202407"},{"key":"2018112909364726000_44.3.334.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01418.x"},{"key":"2018112909364726000_44.3.334.33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056291"},{"key":"2018112909364726000_44.3.334.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04682.x"},{"key":"2018112909364726000_44.3.334.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.06.002"},{"key":"2018112909364726000_44.3.334.36","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.12"},{"key":"2018112909364726000_44.3.334.37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130133"},{"key":"2018112909364726000_44.3.334.38","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070771"},{"key":"2018112909364726000_44.3.334.39","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50145"},{"key":"2018112909364726000_44.3.334.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"2018112909364726000_44.3.334.41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40272-015-0128-2","article-title":"The future is now: biologics for non-infectious pediatric anterior uveitis","volume":"17","author":"Lerman","year":"2015","journal-title":"Paediatr Drugs"},{"key":"2018112909364726000_44.3.334.42","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120583"},{"key":"2018112909364726000_44.3.334.43","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-303935"},{"key":"2018112909364726000_44.3.334.44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ajo.2015.04.016","article-title":"Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors","volume":"160","author":"Lerman","year":"2015","journal-title":"Am J Ophthalmol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.160072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T19:15:26Z","timestamp":1543518926000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.160072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,15]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,1]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.3899\/jrheum.160072"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.160072","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,15]]}}}